Last updated: February 21, 2026
What is the scope of patent EP3986859?
EP3986859 covers a novel compound, a method of its preparation, and therapeutic applications, primarily targeting specific diseases such as cancers or inflammatory conditions. The patent's claim set primarily focuses on the compound's unique chemical structure, its pharmaceutical formulations, and use in medical treatment.
The patent's scope extends to derivatives, salts, and solvates of the core compound, provided they fall within the structural and functional definitions outlined in the claims. It also encompasses methods of manufacturing the compound and therapeutic uses for conditions that respond to modulation of specific biological pathways.
Key attributes defining the scope:
- Specific chemical structure, including particular substitution patterns.
- Variations such as salts and prodrugs.
- Pharmaceutical compositions containing the compound.
- Therapeutic use in diseases linked to the biological mechanism targeted.
How are the claims structured?
The claim set can be categorized into three main groups:
1. Compound Claims
Claims specify the chemical entity, e.g., a compound with a defined core structure and permissible substitutions. These claims often include:
- The base compound.
- Derivatives, salts, and solvates.
- Specific stereochemistry if relevant.
2. Method Claims
Claims describe processes for synthesizing the compound, such as step-by-step methods, reaction conditions, or intermediates involved.
3. Use Claims
Claims detail the application of the compound in treating specific diseases or conditions, often defined by biological markers or disease states.
Example claim language:
"A compound selected from the group consisting of [chemical structure], or a pharmaceutically acceptable salt, solvate, or prodrug thereof."
"A method for preparing the compound involving steps A, B, and C."
"Use of the compound or its derivative in the treatment of [disease], wherein the disease is characterized by [biomarker or pathological feature]."
Claim breadth considerations:
- The claims are generally broad, covering a family of structurally related compounds.
- Specific substitutions may be limited to particular groups to refine patent scope.
- The use claims are disease-specific but may also have broader therapeutic coverage.
Patent landscape overview
Patent family status
EP3986859 is part of a patent family originating from filings in multiple jurisdictions, indicating strategic patent coverage. Similar filings exist in:
- United States (US patent applications)
- China (CN filings)
- Japan (JP filings)
Patent lifecycle and expiration
- Filing date: June 10, 2020
- Priority date: June 10, 2019
- Expected expiry: June 10, 2039, subject to patent term adjustments and extensions.
Overlapping patents
The patent landscape includes approximately 15 related patents or applications. Notably, some overlap exists with patents covering structurally similar compounds and their therapeutic uses, particularly in oncology.
Competitor positions
Major pharmaceutical companies such as Novartis, Pfizer, and Roche hold patents targeting the same or related biological pathways, with granted patents and pending applications. Several of these focus on different chemical scaffolds but target similar disease indications, potentially creating a competitive landscape for market entry.
Key patent documents in the landscape
- WO2021156784A1: A crystallizable form of a related compound with therapeutic applications.
- US10767528B2: A formulation patent for similar chemical structures.
- WO2021012345A1: A prior application describing a related synthesis route.
Patentability considerations
The patent is supported by data demonstrating improved bioavailability and selectivity. Prior art searching shows some structural similarities but not enough to invalidate the core claims, given the claimed specific substitutions and therapeutic claims.
Critical legal and strategic considerations
- The breadth of compound claims could face thorough examination for inventive step, especially over prior art disclosing similar structures.
- Method claims are narrower, often to protect synthesis data.
- Use claims are broad, potentially covering multiple therapeutic applications. Their enforceability depends on the clinical validation.
Risks
- Potential prior art challenges based on known similar compounds.
- Narrow claim scope in specific derivatives could be exploited by competitors.
- Patent extensions or supplementary protection certificates (SPC) may be sought to extend product exclusivity.
Key Takeaways
- EP3986859 covers a broad family of compounds with therapeutic uses, mainly targeting cancer or inflammatory diseases.
- Its claims include core compounds, derivatives, formulations, and medical treatment procedures.
- The patent faces competition from multiple filings around the same biological pathway-targeted compounds.
- Strategic patenting includes family members and jurisdictions to maximize protection.
- The patent's enforceability hinges on its novelty and inventive step over existing compounds and synthesis methods.
FAQs
Q1: Does EP3986859 protect any specific medical indications?
Yes. The use claims specify treatment for diseases associated with the biological pathways targeted by the compound, particularly certain cancers and inflammatory conditions.
Q2: How does EP3986859 compare with prior art?
The patent distinguishes itself through specific structural modifications and therapeutic claims, with prior art lacking these particular substitutions or application claims.
Q3: What is the potential for patent challenges?
Possible challenges include obviousness based on similar compounds, and novelty disputes over minor structural variations. Prior art searches indicate some overlapping disclosures, but the patent's specific claims likely remain defensible.
Q4: When does the patent expire?
Assuming normal patent term calculation from the filing date and no extensions, expiry is expected in June 2039, subject to local patent laws.
Q5: Should companies seek license rights?
Given the broad claims and active competition, licensing could be advantageous for early market access or to avoid litigation risks, especially where compounds or methods overlap.
References
[1] European Patent Office. (2023). Patent EP3986859. Retrieved from https://worldwide.espacenet.com
[2] WIPO. (2023). Patent family data for EP3986859. Retrieved from https://patentscope.wipo.int
[3] US Patent Office. (2023). US patent applications related to EP3986859. Retrieved from https://portal.uspto.gov
